Regenerative medicine
PHI’s new CEO: ”I am excited to lead us forward with new energy”
Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences...
PHI’s CEO comments on the approved US listing
Phase Holographic Imaging has been approved for a...
PHI: “It’s the right moment to capitalize on regenerative medicine momentum”
Medtech company Phase Holographic Imaging recently secured a...
Shift to regenerative medicine increases growth prospects for PHI
With a sharp focus on expanding its market...
PHI links up with two regenerative medicine networks
In 2023, Phase Holographic Imaging has solidified its...
PHI charts a bold course to impact regenerative medicine
Swedish medtech company PHI released its year-end report...
PHI’s CEO reflects on global roadshow success
During the early summer, medical technology company PHI...
PHI on how TO 3 proceeds will be used
On May 2, the redemption period of Phase...
PHI´s CEO comments on latest advancements
In 2022, medtech company Phase Holographic Imaging conducted...
Fluicell satsar på regenerativ medicin
Regenerativ medicin är ett framväxande forskningsområde som fokuserar...
Notiser
Ultomiris visar stark överlevnad i HSCT-TMA-studie
Circio presenterar lovande TG01-data
Cinclus Pharma slipper barnstudier för linaprazan glurate
Thor Medical tecknar avtal värt 200 MNOK
Genmabs Epcoritamab visar höga responsnivåer i DLBCL-studie
NYHETSBREV
NYHETER
Lovande 4-månadersdata från Cerenos Expanded Access Program
AcuCort stärker lansering med TO2-injektion
AstraZeneca i miljardavtal inom AI
Kommande event!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Bispecifikt och kinesiskt det nya svarta inom cancer
Riskkapitalcykeln fullständig – vi är tillbaka där vi började
